Market Executive Summary

REPORT HIGHLIGHT
The asthma therapeutics market is estimated to represent a global market of USD 19.8 billion by 2017 with growth rate of 1.9%. Key drivers of the market include rising prevalence of asthma and other respiratory disorders. As per the World Health Organization (WHO), more than 235 million people suffer from asthma globally. Around 3,38,000 deaths were reported in 2017 and most deaths occur among older adults. Further, introduction of technologically advanced products and rising awareness levels about these disorders is anticipated to drive the market growth. Rising research in the field of biologics for asthma treatment is seen as most promising opportunity. Biologics targeting pro-inflammatory cytokines and other inflammatory mediators may be of therapeutic benefit. However, expiry of leading branded drugs such as Singulair (montelukast sodium), Symbicort (budesonide/formoterol fumarate), Advair (fluticasone propionate/salmeterol xinafoate), and Xolair (omalizumab) is anticipated to hamper the market growth.
The global Asthma therapeutics market is segmented on the basis of drug class, product, route of administration and region. On the basis of drug class, the market is segmented into anti- inflammatory, bronchodilators and combination therapy. Combination therapy dominated the market share owing to its high adoption rates and utilization. Anti- inflammatory drugs are expected to witness market growth owing to R&D developments pertaining to biologics. Patent expiration of anti- inflammatory drugs during the forecast period will have impact on the revenue generation. Anti- inflammatory segment is expected to witness the fastest market growth.
On the basis of products offered by companies, the market is segmented into inhalers and nebulizers. Inhalers are most widely adopted owing to the patient compliance and ease of administration. They held the leading position in the market. Amongst inhalers, metered dose inhalers have been widely adopted due to their application in the long term therapy. Nebulizers are anticipated to grow at the highest CAGR during the forecast period.
On the basis of route of administration, the market is segmented into oral, inhaled and other routes. Inhaled route of administration accounted for the largest revenue in the year 2017. This is due to effective pharmacodynamics and pharmacokinetic actions upon administration of drug dose by this route. Oral route of administration is expected to emerge as the fastest growing market over the forecast period.
Geographically, the market is represented as North America, Europe, Asia Pacific, Latin America and Middle East and Africa. North America dominated the overall asthma therapeutics market in terms of revenue share in 2014 at over 50.0%. The escalated incidence rate of asthma, increased awareness levels pertaining to treatment options, and the rising adoption of inhaled therapeutics are some of the major factors attributing the largest revenue share of this region. The European market is set to witness steady growth mainly due to the presence of a considerably developed pharmaceutical industry and the significant demand for asthma-related therapeutics. With the increasing geriatric population, susceptible to acquire respiratory conditions, such as asthma, will further support to the growth of regional market in the U.S.
Some of the key players in this industry include AstraZeneca Plc, Philips Healthcare, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Plc, Sanofi-Aventis SA, CareFusion Corporation, Sunovion Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Roche Diagnostics, and Merck & Co., Inc. The market for asthma therapeutics is expected to experience steady growth primarily due to the branded drugs approaching their impending patent expiration dates and the intensive generic competition in the developing nations.
The market size and forecast for each segment has been provided for the period 2014 to 2028, considering 2017 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2017 to 2028 for every reported segment.
The years considered for the study are:
Historical Year ? 2014 & 2017
Base Year ? 2017
Estimated Year ? 2017
Projected Year ? 2028
TARGET AUDIENCE
Traders, Distributors, And Suppliers
Manufacturers
Hospitals
Government and Regional Agencies and Research Organizations
Consultants
Distributors
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
MARKET, BY DRUG CLASSS
Anti-inflammatory
Bronchodilators
Combination Therapy
MARKET, BY PRODUCTS
Inhalers
Nebulizers
MARKET, BY ROUTE
Oral
Inhaled
Subcutaneous
Intravenous
MARKET, BY REGION
North America
Europe
Asia Pacific
Rest of the World
MARKET, BY COUNTRY
Further Breakdown of The North America Market
U.S.
Canada
Further Breakdown of The Europe Market
Germany
France
Rest of Europe
Further Breakdown of The APAC Market
India
China
Rest of APAC
Further Breakdown of The Rest of the World Market
Middle East and Africa
Latin America